Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schools, Medical | 3 | 2021 | 208 | 0.960 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2006 | 42 | 0.900 |
Why?
|
| Cultural Diversity | 1 | 2021 | 193 | 0.590 |
Why?
|
| Students, Medical | 1 | 2021 | 158 | 0.570 |
Why?
|
| Milk, Human | 1 | 2018 | 51 | 0.560 |
Why?
|
| Breast Feeding | 1 | 2018 | 126 | 0.510 |
Why?
|
| Health Status Disparities | 3 | 2018 | 719 | 0.510 |
Why?
|
| Postmenopause | 2 | 2005 | 141 | 0.410 |
Why?
|
| Estrogens | 2 | 2013 | 203 | 0.400 |
Why?
|
| Menopause | 4 | 2007 | 64 | 0.360 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.350 |
Why?
|
| Kidney Diseases | 1 | 2013 | 172 | 0.340 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.330 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2006 | 12 | 0.290 |
Why?
|
| Cardiovascular Diseases | 3 | 2013 | 749 | 0.290 |
Why?
|
| Estradiol | 3 | 2007 | 268 | 0.250 |
Why?
|
| Contraceptive Agents, Female | 1 | 2006 | 25 | 0.240 |
Why?
|
| Bone Density | 1 | 2006 | 103 | 0.230 |
Why?
|
| Medroxyprogesterone | 2 | 2002 | 2 | 0.230 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2002 | 11 | 0.230 |
Why?
|
| Ethinyl Estradiol | 2 | 2002 | 11 | 0.230 |
Why?
|
| Complementary Therapies | 1 | 2005 | 51 | 0.230 |
Why?
|
| Hot Flashes | 4 | 2005 | 8 | 0.220 |
Why?
|
| Humans | 22 | 2021 | 43102 | 0.210 |
Why?
|
| Women's Health | 1 | 2005 | 160 | 0.210 |
Why?
|
| Exercise Therapy | 1 | 2004 | 87 | 0.200 |
Why?
|
| Momordica | 1 | 2022 | 14 | 0.190 |
Why?
|
| Female | 19 | 2021 | 24698 | 0.190 |
Why?
|
| United States | 5 | 2021 | 5205 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 196 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 706 | 0.170 |
Why?
|
| History, 20th Century | 1 | 2021 | 121 | 0.160 |
Why?
|
| Endometriosis | 1 | 2002 | 83 | 0.160 |
Why?
|
| Oocyte Donation | 1 | 2010 | 1 | 0.160 |
Why?
|
| Educational Measurement | 1 | 2021 | 102 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 56 | 0.160 |
Why?
|
| Catechin | 2 | 2010 | 39 | 0.150 |
Why?
|
| Antisickling Agents | 1 | 2009 | 14 | 0.150 |
Why?
|
| Hypogonadism | 1 | 2009 | 23 | 0.150 |
Why?
|
| Educational Status | 1 | 2021 | 339 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2009 | 34 | 0.150 |
Why?
|
| Milk Banks | 1 | 2018 | 3 | 0.150 |
Why?
|
| Infertility, Male | 1 | 2009 | 47 | 0.150 |
Why?
|
| Minority Groups | 3 | 2021 | 690 | 0.150 |
Why?
|
| Uterine Neoplasms | 2 | 2010 | 53 | 0.140 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 415 | 0.140 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 41 | 0.140 |
Why?
|
| Leiomyoma | 2 | 2010 | 42 | 0.140 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2018 | 36 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 161 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 590 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 179 | 0.130 |
Why?
|
| Chemotactic Factors | 1 | 2007 | 8 | 0.130 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 18 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 187 | 0.130 |
Why?
|
| HIV-1 | 1 | 2022 | 755 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 235 | 0.120 |
Why?
|
| Chemokines | 1 | 2007 | 96 | 0.120 |
Why?
|
| Medicare | 1 | 2019 | 332 | 0.120 |
Why?
|
| Carcinoma | 1 | 2007 | 108 | 0.120 |
Why?
|
| Healthy People Programs | 1 | 2005 | 25 | 0.110 |
Why?
|
| Public Health Administration | 1 | 2005 | 26 | 0.110 |
Why?
|
| Infant | 1 | 2018 | 1175 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1455 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 55 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2005 | 178 | 0.100 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2002 | 21 | 0.090 |
Why?
|
| Accreditation | 1 | 2012 | 19 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2002 | 104 | 0.090 |
Why?
|
| Georgia | 1 | 2012 | 192 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2012 | 146 | 0.080 |
Why?
|
| Middle Aged | 6 | 2007 | 12222 | 0.080 |
Why?
|
| Animals | 7 | 2018 | 16992 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 77 | 0.070 |
Why?
|
| HIV Infections | 1 | 2022 | 2586 | 0.070 |
Why?
|
| Vulnerable Populations | 1 | 2009 | 166 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2007 | 8 | 0.060 |
Why?
|
| Cystitis | 1 | 2007 | 7 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 44 | 0.060 |
Why?
|
| Health Personnel | 1 | 2009 | 277 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2007 | 45 | 0.060 |
Why?
|
| Osteocalcin | 1 | 2006 | 5 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2007 | 61 | 0.060 |
Why?
|
| Male | 4 | 2021 | 23409 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 502 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2007 | 154 | 0.060 |
Why?
|
| Antioxidants | 1 | 2010 | 443 | 0.060 |
Why?
|
| Female Urogenital Diseases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 41 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 49 | 0.060 |
Why?
|
| Social Justice | 2 | 2011 | 65 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 55 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2006 | 114 | 0.060 |
Why?
|
| Urogenital System | 1 | 2005 | 2 | 0.060 |
Why?
|
| Vasomotor System | 1 | 2005 | 3 | 0.060 |
Why?
|
| Apoptosis | 2 | 2010 | 1568 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2005 | 49 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 51 | 0.060 |
Why?
|
| Ovarian Follicle | 1 | 2005 | 44 | 0.050 |
Why?
|
| Mice | 5 | 2010 | 6644 | 0.050 |
Why?
|
| Reproduction | 1 | 2005 | 94 | 0.050 |
Why?
|
| Lipids | 1 | 2006 | 256 | 0.050 |
Why?
|
| Plant Extracts | 2 | 2022 | 302 | 0.050 |
Why?
|
| Body Weight | 1 | 2006 | 429 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2004 | 77 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 1234 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 508 | 0.050 |
Why?
|
| Aged | 4 | 2007 | 8214 | 0.050 |
Why?
|
| Estradiol Congeners | 1 | 2002 | 2 | 0.050 |
Why?
|
| Progesterone Congeners | 1 | 2002 | 2 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 14 | 0.050 |
Why?
|
| Danazol | 1 | 2002 | 3 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2002 | 8 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2002 | 39 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 48 | 0.040 |
Why?
|
| Endometrium | 1 | 2002 | 59 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2006 | 1600 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 152 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2006 | 1759 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 195 | 0.040 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2010 | 1 | 0.040 |
Why?
|
| Embryo Research | 1 | 2010 | 2 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 375 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2010 | 8 | 0.040 |
Why?
|
| Health Services Research | 1 | 2011 | 161 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2010 | 47 | 0.040 |
Why?
|
| Quality of Life | 1 | 2005 | 616 | 0.040 |
Why?
|
| Adult | 3 | 2007 | 13872 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2010 | 47 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 44 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 138 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 223 | 0.040 |
Why?
|
| Depression | 1 | 2005 | 863 | 0.040 |
Why?
|
| Testis | 1 | 2009 | 207 | 0.030 |
Why?
|
| Research Design | 1 | 2010 | 385 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2007 | 39 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 188 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 665 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 310 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 239 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 541 | 0.030 |
Why?
|
| Boston | 1 | 2005 | 32 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 310 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 384 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2005 | 38 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2009 | 2157 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2007 | 358 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 148 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1596 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 249 | 0.020 |
Why?
|
| Camellia sinensis | 1 | 2009 | 3 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 367 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 76 | 0.020 |
Why?
|
| Models, Educational | 1 | 2009 | 46 | 0.020 |
Why?
|
| Tea | 1 | 2009 | 46 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2009 | 36 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 3994 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 152 | 0.020 |
Why?
|
| Prejudice | 1 | 2009 | 116 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 408 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2009 | 232 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 32 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 15 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 80 | 0.020 |
Why?
|
| Fimbriae Proteins | 1 | 2007 | 25 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 33 | 0.020 |
Why?
|
| Butyrates | 1 | 2007 | 34 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 107 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 44 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 51 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2007 | 127 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 101 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1124 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 166 | 0.020 |
Why?
|
| Anovulation | 1 | 2005 | 4 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2005 | 16 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2005 | 47 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 61 | 0.010 |
Why?
|
| Estrous Cycle | 1 | 2005 | 37 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 43 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 1857 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 458 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 883 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 436 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 667 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 592 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2007 | 460 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 652 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1723 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 1035 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1271 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 1869 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 1772 | 0.010 |
Why?
|
Montgomery Rice's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(14)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_